10-Q 1 svra-20220930.htm 10-Q 10-Q
--12-31Q3false00011603080001160308us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001160308us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300001160308svra:ClassOfWarrantOneMember2022-01-012022-09-300001160308us-gaap:EmployeeStockOptionMember2021-12-310001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001160308us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-09-300001160308us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-3000011603082021-01-012021-03-310001160308srt:MaximumMembersvra:HCWainwrightAndCoLLCMember2017-04-280001160308us-gaap:RetainedEarningsMember2021-12-310001160308us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001160308us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001160308svra:EvercoreGroupLLCMember2021-07-060001160308svra:TwoThousandSeventeenPreFundedWarrantsMember2021-12-310001160308us-gaap:StockCompensationPlanMember2021-01-012021-09-300001160308svra:TermLoanMembersvra:LoanAndSecurityAgreementMembersvra:SiliconValleyBankMember2022-04-210001160308svra:TermLoanMembersvra:LoanAndSecurityAgreementMembersvra:SiliconValleyBankMember2017-04-280001160308svra:SavaraApSMember2022-01-012022-09-300001160308svra:PublicOfferingMember2021-03-152021-03-150001160308svra:HCWainwrightAndCoLLCMember2022-01-012022-09-300001160308svra:TermLoanMembersvra:LoanAndSecurityAgreementMembersvra:SiliconValleyBankMembersvra:AfterFirstAndBeforeSecondAnniversaryClosingDateMember2022-04-212022-04-210001160308us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001160308us-gaap:RetainedEarningsMember2020-12-310001160308svra:TwoThousandTwentyOneInducementEquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001160308svra:ClassOfWarrantTwoMember2022-01-012022-09-300001160308us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001160308us-gaap:RetainedEarningsMember2022-01-012022-03-310001160308us-gaap:RestrictedStockUnitsRSUMember2022-09-300001160308us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001160308srt:MaximumMembersvra:EvercoreGroupLLCMember2021-07-060001160308us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310001160308us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001160308us-gaap:RetainedEarningsMember2021-06-300001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001160308svra:TwoThousandSeventeenPreFundedWarrantsMember2022-09-300001160308us-gaap:AdditionalPaidInCapitalMember2022-03-310001160308us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001160308svra:NebulizerMember2022-01-012022-09-300001160308us-gaap:EmployeeStockOptionMember2022-09-300001160308svra:ClassOfWarrantFiveMember2022-09-300001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001160308us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300001160308svra:TwoThousandAndTwentyOnePreFundedWarrantsMember2021-03-152021-03-150001160308svra:HCWainwrightAndCoLLCMember2021-01-012021-09-300001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001160308us-gaap:RetainedEarningsMember2021-07-012021-09-300001160308svra:DecemberTwoThousandEighteenWarrantsMember2021-12-310001160308us-gaap:CommonStockMember2022-07-012022-09-300001160308us-gaap:RetainedEarningsMember2021-01-012021-03-310001160308us-gaap:AdditionalPaidInCapitalMember2021-12-310001160308svra:EvercoreGroupLLCMember2021-07-162021-07-160001160308svra:ActivePharmaceuticalIngredientsMember2022-01-012022-09-300001160308svra:ClassOfWarrantThreeMember2022-09-300001160308us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001160308svra:TwoThousandEightStockOptionPlanAndTwoThousandFifteenOmnibusIncentiveOptionPlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001160308svra:TwoThousandAndEightStockOptionPlanMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001160308svra:LoanAndSecurityAgreementMembersvra:SiliconValleyBankMember2017-04-262017-04-280001160308svra:ClassOfWarrantFourMember2022-09-3000011603082022-03-3100011603082021-09-3000011603082021-01-012021-12-310001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001160308us-gaap:ProductMember2022-01-012022-09-300001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001160308us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001160308svra:WarrantRepurchaseMember2021-03-150001160308svra:PublicOfferingMember2021-03-150001160308us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300001160308us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001160308svra:HCWainwrightAndCoLLCMember2021-07-122021-07-120001160308us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-3000011603082022-11-100001160308us-gaap:WarrantMember2021-01-012021-09-300001160308svra:NonvestedRestrictedSharesAndRestrictedStockUnitsMember2021-01-012021-09-300001160308us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001160308us-gaap:AssetBackedSecuritiesMember2021-12-310001160308svra:TermLoanMembersvra:LoanAndSecurityAgreementMembersvra:BeforeFirstAnniversaryClosingDateMembersvra:SiliconValleyBankMember2022-04-212022-04-210001160308us-gaap:AdditionalPaidInCapitalMember2022-09-300001160308svra:PreFundedPIPEWarrantsMember2021-12-310001160308us-gaap:CommonStockMembersvra:HCWainwrightAndCoLLCMember2018-06-272018-06-280001160308us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001160308us-gaap:RetainedEarningsMember2021-04-012021-06-300001160308us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001160308us-gaap:RetainedEarningsMember2022-07-012022-09-300001160308us-gaap:CommercialPaperMember2021-12-3100011603082022-01-012022-03-310001160308us-gaap:CommonStockMember2021-06-300001160308svra:ClassOfWarrantOneMember2022-09-300001160308us-gaap:RetainedEarningsMember2021-09-300001160308us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-3000011603082021-03-152021-03-150001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001160308us-gaap:AdditionalPaidInCapitalMember2020-12-3100011603082022-09-3000011603082021-07-012021-09-300001160308svra:TwoThousandAndTwentyOnePreFundedWarrantsMember2021-12-310001160308us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001160308svra:NonvestedRestrictedSharesAndRestrictedStockUnitsMember2022-01-012022-09-300001160308svra:AprilTwoThousandSeventeenWarrantsMember2022-09-300001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001160308us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001160308us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001160308svra:TermLoanMembersvra:LoanAndSecurityAgreementMembersrt:MaximumMembersvra:SiliconValleyBankMember2022-04-210001160308us-gaap:CommonStockMember2021-07-012021-09-300001160308svra:JuneTwoThousandSeventeenWarrantsMember2022-09-300001160308svra:TwoThousandAndTwentyOnePreFundedWarrantsMember2022-09-300001160308svra:TermLoanMembersvra:LoanAndSecurityAgreementMembersvra:SiliconValleyBankMember2017-04-262017-04-280001160308us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-12-310001160308us-gaap:CommonStockMember2021-04-012021-06-300001160308us-gaap:RetainedEarningsMember2022-06-300001160308svra:PublicOfferingMember2021-03-052021-03-050001160308us-gaap:CommonStockMember2022-03-310001160308us-gaap:AdditionalPaidInCapitalMember2022-06-300001160308svra:TwoThousandEightStockOptionPlanAndTwoThousandFifteenOmnibusIncentiveOptionPlanMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001160308us-gaap:RetainedEarningsMember2022-09-300001160308svra:MilestoneWarrantsMembersvra:WarrantRepurchaseMember2021-03-152021-03-150001160308us-gaap:USGovernmentDebtSecuritiesMember2021-12-310001160308svra:AmendedAndRestatedTwoThousandAndFifteenOmnibusIncentivePlanMember2022-09-300001160308us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001160308us-gaap:WarrantMember2022-01-012022-09-300001160308us-gaap:AdditionalPaidInCapitalMember2021-06-300001160308us-gaap:CorporateDebtSecuritiesMember2021-12-310001160308us-gaap:AccumulatedTranslationAdjustmentMember2022-09-3000011603082022-04-012022-06-300001160308svra:TwoThousandTwentyOneInducementEquityIncentivePlanMember2022-09-300001160308us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-12-3100011603082022-01-012022-09-300001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001160308us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001160308svra:ActivePharmaceuticalIngredientsMember2022-09-3000011603082021-03-310001160308svra:AprilTwoThousandSeventeenWarrantsMember2021-12-310001160308us-gaap:CommonStockMember2021-12-310001160308us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300001160308us-gaap:CommonStockMember2022-06-300001160308us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001160308us-gaap:PrepaidExpensesAndOtherCurrentAssetsMembersvra:SavaraApSMember2021-12-310001160308svra:DecemberTwoThousandEighteenWarrantsMember2022-09-300001160308us-gaap:USGovernmentDebtSecuritiesMember2022-09-300001160308us-gaap:RetainedEarningsMember2021-03-3100011603082021-12-310001160308us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001160308svra:ClassOfWarrantThreeMember2022-01-012022-09-300001160308svra:TermLoanMembersvra:LoanAndSecurityAgreementMembersvra:SiliconValleyBankMember2022-04-212022-04-210001160308us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-3000011603082021-06-300001160308us-gaap:CommonStockMember2021-09-300001160308us-gaap:RetainedEarningsMember2022-03-310001160308svra:TwoThousandTwentyOneInducementEquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001160308us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001160308us-gaap:CommonStockMember2022-09-300001160308svra:MilestoneWarrantsMembersvra:WarrantRepurchaseMember2021-08-132021-08-130001160308svra:ClassOfWarrantFourMember2022-01-012022-09-300001160308svra:EvercoreGroupLLCMember2022-01-012022-09-300001160308us-gaap:CommonStockMember2021-01-012021-03-310001160308svra:EvercoreGroupLLCMember2021-01-012021-09-300001160308svra:ClassOfWarrantTwoMember2022-09-3000011603082021-04-012021-06-300001160308us-gaap:CommonStockMember2021-03-310001160308svra:SavaraApSMemberus-gaap:OtherNoncurrentAssetsMember2022-09-300001160308svra:ClassOfWarrantFiveMember2022-01-012022-09-300001160308svra:PreFundedPIPEWarrantsMember2022-09-3000011603082022-06-300001160308us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001160308svra:JuneTwoThousandSeventeenWarrantsMember2021-12-310001160308us-gaap:CommonStockMember2022-01-012022-03-310001160308us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001160308us-gaap:CommercialPaperMember2022-09-300001160308us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001160308svra:TermLoanMembersvra:LoanAndSecurityAgreementMembersvra:SiliconValleyBankMember2022-01-012022-09-300001160308us-gaap:RestrictedStockUnitsRSUMember2021-12-310001160308us-gaap:CommonStockMember2022-04-012022-06-300001160308us-gaap:RetainedEarningsMember2022-04-012022-06-300001160308us-gaap:AdditionalPaidInCapitalMember2021-09-3000011603082021-01-012021-09-3000011603082020-12-310001160308us-gaap:CommonStockMember2021-03-152021-03-150001160308us-gaap:CommonStockMember2020-12-310001160308us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001160308us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001160308us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001160308us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001160308us-gaap:AdditionalPaidInCapitalMember2021-03-310001160308us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001160308us-gaap:StockCompensationPlanMember2022-01-012022-09-3000011603082022-07-012022-09-3000011603082021-03-052021-03-05svra:Segmentxbrli:purexbrli:sharesiso4217:USDiso4217:USDxbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-32157

 

img197170111_0.jpg 

Savara Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

84-1318182

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

 

6836 Bee Cave Road, Building III, Suite 201

Austin, TX

 

78746

(Address of principal executive offices)

 

(Zip Code)

(512) 614-1848

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

SVRA

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

As of November 10, 2022, the registrant had 114,044,001 shares of common stock, $0.001 par value per share, outstanding.


 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements (Unaudited)

 

 

Condensed Consolidated Balance Sheets

1

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

2

 

Consolidated Statements of Changes in Stockholders’ Equity

3

 

Condensed Consolidated Statements of Cash Flows

5

 

Notes to Condensed Consolidated Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

23

Item 4.

Controls and Procedures

23

PART II.

OTHER INFORMATION

24

Item 1.

Legal Proceedings

24

Item 1A.

Risk Factors

24

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

24

Item 3.

Defaults Upon Senior Securities

24

Item 4.

Mine Safety Disclosures

24

Item 5.

Other Information

24

Item 6.

Exhibits

24

Exhibit Index

25

Signatures

26

 

 

i


 

PART I—FINANCIAL INFORMATION

Item I. Financial Information

 

Savara Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

 

 

 

September 30, 2022

 

 

December 31, 2021

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

119,841

 

 

$

34,012

 

Short-term investments

 

 

14,236

 

 

 

127,159

 

Prepaid expenses and other current assets

 

 

2,992

 

 

 

3,829

 

Total current assets

 

 

137,069

 

 

 

165,000

 

Property and equipment, net

 

 

59

 

 

 

73

 

In-process R&D

 

 

9,754

 

 

 

11,274

 

Other non-current assets

 

 

876

 

 

 

251

 

Total assets

 

$

147,758

 

 

$

176,598

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

893

 

 

$

1,443

 

Accrued expenses and other current liabilities

 

 

4,270

 

 

 

4,884

 

Current portion of long-term debt

 

 

 

 

 

8,333

 

Total current liabilities

 

 

5,163

 

 

 

14,660

 

Long-term liabilities:

 

 

 

 

 

 

Long-term debt

 

 

26,010

 

 

 

17,323

 

Other long-term liabilities

 

 

71

 

 

 

117

 

Total liabilities

 

 

31,244

 

 

 

32,100

 

Commitments and contingencies (Note 9)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.001 par value, 300,000,000 authorized as of September 30, 2022 and
   December 31, 2021;
114,042,642 and 114,036,892 shares issued and outstanding
   as of September 30, 2022 and December 31, 2021, respectively

 

 

116

 

 

 

116

 

Additional paid-in capital

 

 

446,376

 

 

 

444,898

 

Accumulated other comprehensive (loss) income

 

 

(1,607

)

 

 

5

 

Accumulated deficit

 

 

(328,371

)

 

 

(300,521

)

Total stockholders’ equity

 

 

116,514

 

 

 

144,498

 

Total liabilities and stockholders’ equity

 

$

147,758

 

 

$

176,598

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

1


 

Savara Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

For the three months ended September 30,

 

 

For the nine months ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

8,151

 

 

$

6,532

 

 

 

20,253

 

 

 

21,373

 

General and administrative

 

 

2,376

 

 

 

3,400

 

 

 

7,687

 

 

 

9,331

 

Depreciation and amortization

 

 

8

 

 

 

40

 

 

 

24

 

 

 

134

 

Total operating expenses

 

 

10,535

 

 

 

9,972

 

 

 

27,964

 

 

 

30,838

 

Loss from operations

 

 

(10,535

)

 

 

(9,972

)

 

 

(27,964

)

 

 

(30,838

)

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense)

 

 

152

 

 

 

(566

)

 

 

(702

)

 

 

(1,717

)

Foreign currency exchange (loss) gain

 

 

(8

)

 

 

(8

)

 

 

21

 

 

 

(22

)

Tax credit income

 

 

5

 

 

 

 

 

 

795

 

 

 

873

 

Total other income (expense), net

 

 

149

 

 

 

(574

)

 

 

114

 

 

 

(866

)

Net loss

 

$

(10,386

)

 

$

(10,546

)

 

$

(27,850

)

 

$

(31,704

)

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.07

)

 

$

(0.07

)

 

$

(0.18

)

 

$

(0.25

)

Weighted-average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

152,773,015

 

 

 

152,587,848

 

 

 

152,771,302

 

 

 

127,623,824

 

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Loss on foreign currency translation

 

 

(668

)

 

 

(297

)

 

 

(1,621

)

 

 

(645

)

Unrealized gain (loss) on short-term
   investments

 

 

77

 

 

 

(10

)

 

 

9

 

 

 

(12

)

Total comprehensive loss

 

$

(10,977

)

 

$

(10,853

)

 

$

(29,462

)

 

$

(32,361

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2


 

Savara Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity

Periods Ended September 30, 2022 and 2021

(In thousands, except share amounts)

(Unaudited)

 

 

 

Stockholders’ Equity

 

 

 

Common Stock

 

 

 

 

 

 

 

 

 

 

 

 

Number of
Shares

 

 

Amount

 

 

Additional
Paid-In
Capital

 

 

Accumulated
Deficit

 

 

Accumulated
Other
Comprehensive
Income (Loss)

 

 

Total

 

Balance on December 31, 2021

 

 

114,036,892

 

 

$

116

 

 

$

444,898

 

 

$

(300,521

)

 

$

5

 

 

$

144,498

 

Issuance of common stock for
  settlement of RSUs

 

 

3,688

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repurchase of shares for
  minimum tax withholdings

 

 

(720

)

 

 

 

 

 

(1

)

 

 

 

 

 

 

 

 

(1

)

Stock-based compensation

 

 

 

 

 

 

 

 

574

 

 

 

 

 

 

 

 

 

574

 

Foreign exchange translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(208

)

 

 

(208

)

Unrealized loss on short-term
  investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(88

)

 

 

(88

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(8,300

)

 

 

 

 

 

(8,300

)

Balance on March 31, 2022

 

 

114,039,860

 

 

$

116

 

 

$

445,471

 

 

$

(308,821

)

 

$

(291

)

 

$

136,475

 

Issuance of common stock for
  settlement of RSUs

 

 

1,812

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repurchase of shares for
  minimum tax withholdings

 

 

(401

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

456

 

 

 

 

 

 

 

 

 

456

 

Foreign exchange translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(745

)

 

 

(745

)

Unrealized gain on short-term
  investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

20

 

 

 

20

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(9,164

)

 

 

 

 

 

(9,164

)

Balance on June 30, 2022

 

 

114,041,271

 

 

$

116

 

 

$

445,927

 

 

$

(317,985

)

 

$

(1,016

)

 

$

127,042

 

Issuance of common stock for
  settlement of RSUs

 

 

1,813

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repurchase of shares for
  minimum tax withholdings

 

 

(442

)

 

 

 

 

 

(1

)

 

 

 

 

 

 

 

 

(1

)

Stock-based compensation

 

 

 

 

 

 

 

 

450

 

 

 

 

 

 

 

 

 

450

 

Foreign exchange translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(668

)

 

 

(668

)

Unrealized gain on short-term
  investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

77

 

 

 

77

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(10,386

)

 

 

 

 

 

(10,386

)

Balance on September 30, 2022

 

 

114,042,642

 

 

$

116

 

 

$

446,376

 

 

$

(328,371

)

 

$

(1,607

)

 

$

116,514

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3


 

Savara Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity (continued)

Periods Ended September 30, 2022 and 2021

(In thousands, except share amounts)

(Unaudited)

 

 

 

Stockholders’ Equity

 

 

 

Common Stock

 

 

 

 

 

 

 

 

 

 

 

 

Number of
Shares

 

 

Amount

 

 

Additional
Paid-In
Capital

 

 

Accumulated
Deficit

 

 

Accumulated
Other
Comprehensive
Income (Loss)

 

 

Total

 

Balance on December 31, 2020

 

 

54,152,955

 

 

$

55

 

 

$

320,893

 

 

$

(257,507

)

 

$

942

 

 

$

64,383

 

Issuance of common stock and
  pre-funded warrants in public
  offering, net of offering costs
(1)

 

 

57,479,978

 

 

 

57

 

 

 

121,770

 

 

 

 

 

 

 

 

 

121,827

 

Repurchase of outstanding
  pre-funded warrants

 

 

 

 

 

 

 

 

(3,909

)

 

 

 

 

 

 

 

 

(3,909

)

Net issuance of common stock
  upon exercise of stock warrants

 

 

1,737,450

 

 

 

2

 

 

 

2,544

 

 

 

 

 

 

 

 

 

2,546

 

Issuance of common stock for
  settlement of RSUs

 

 

5,563

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock upon
  exercise of stock options

 

 

202,708

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

2

 

Stock-based compensation

 

 

 

 

 

 

 

 

946

 

 

 

 

 

 

 

 

 

946

 

Foreign exchange translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(431

)

 

 

(431

)

Unrealized loss on short-term
  investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(26

)

 

 

(26

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(10,217

)

 

 

 

 

 

(10,217

)

Balance on March 31, 2021

 

 

113,578,654

 

 

$

114

 

 

$

442,246

 

 

$

(267,724

)

 

$

485

 

 

$

175,121

 

Issuance of common stock and
  pre-funded warrants in public
  offering, net of offering costs

 

 

 

 

 

 

 

 

321

 

 

 

 

 

 

 

 

 

321

 

Issuance of common stock for
  settlement of RSUs

 

 

203,687

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock upon
  exercise of stock options

 

 

65,191

 

 

 

 

 

 

3

 

 

 

 

 

 

 

 

 

3

 

Stock-based compensation

 

 

 

 

 

 

 

 

771

 

 

 

 

 

 

 

 

 

771

 

Foreign exchange translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

83

 

 

 

83

 

Unrealized gain on short-term
  investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24

 

 

 

24

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(10,941

)

 

 

 

 

 

(10,941

)

Balance on June 30, 2021

 

 

113,847,532

 

 

$

114

 

 

$

443,341

 

 

$

(278,665

)

 

$